Product Description.:
Compare To: Depakote M 473
tablet , film-coated , white , oval oblong
DebossedBiconvex
The information contained in the First DataBank database is intended to supplement the knowledge of physicians, pharmacists,and other healthcare professionals regarding drug therapy problems and patient counseling information. This information is advisory only and is not intended to replacesound clinical judgment in the delivery of healthcare services.
First DataBank disclaims all warranties, whether expressed or implied, including any warranty as to the quality, accuracy, and suitability of this information for any purpose.
Copyright ? 2008 First DataBank, Inc.
Acq Cost: $298.60
Drug Form Cost : $2.9860 TABLET, EXTENDED RELEASE 24 HR
ABC List Price : 06/14/2013$407.49
Wholesale Cost : 06/14/2013$325.99
Sug.Wholesale Price : 06/14/2013$407.49
ABC Contract Management
Contract: 4000000257 PRXO MARKET
Abbrv. Name : PRXO
Contract Cost : $298.60
Start Date: 06/14/2013
End Date: 12/31/9999
Retail
Retail Price :
Retail Margin :
MSRP :
CSRP : $407.49
Promotion Details
Description:
Price:
Order Period:
Shipping Period:
Processing request...
Processing request...
Monthly
UsageVALLEY MEDICAL PHARMACY 0100093972
Detailed Purchase HistoryVALLEY MEDICAL PHARMACY 0100093972
State : Medicaid
State Formulary :
Coverage :
Price :
Previous Price :
Billing Code :
Min Qty : 0
Max Qty : 0
Copay :
Prior Auth :
Refills :
Billing Units :
Pkg Size Divisor : 0
Qty Bill Units :
Fee Ind :
Specific Limitation :
LTC Restriction :
Frequency Restriction :
Code 1 Restriction :
Substitutable Ind :
Medicare
Medicare Coverage :
HCPCS :
Description :
Price :
Previous Price :
FDA Drug Product Efficacy Study and Implementation program (DESI)
DESI Drug Ind :
DESI2 Drug Ind :
Centers for Medicare and Medicaid Services(CMS, formerly HCFA)
FDA Therap Equiv : AB
Unit : TAB
Units Per Pkg : 1.000
FDA Approval Date : 01/29/2009
Market Entry Date : 02/02/2009
Termination Date :
Drug Type Code : 1
Drug Category : N
The information contained in the First DataBank database is intended to supplement the knowledge of physicians, pharmacists,and other healthcare professionals regarding drug therapy problems and patient counseling information. This information is advisory only and is not intended to replacesound clinical judgment in the delivery of healthcare services.
First DataBank disclaims all warranties, whether expressed or implied, including any warranty as to the quality, accuracy, and suitability of this information for any purpose.
Copyright ? 2008 First DataBank, Inc.
Generic Name : DIVALPROEX SODIUM
Route : ORAL
Dose Form : TABLET, EXTENDED RELEASE 24 HR
Strength : 500 mg
AHFS Therapeutic Classifications
28129200 ANTICONVULSANTS, MISCELLANEOUS
28280000 ANTIMANIC AGENTS
28329200 ANTIMIGRAINE AGENTS, MISCELLANEOUS
Active Ingredients CAS
001624 divalproex sodium 076584708
Inactive Ingredients CAS
000915 dextrose 005996101
001911 titanium dioxide 013463677
002438 Cellulose 009004346
002459 Polyethylene Glycol 025322683
002529 Ethylcellulose 009004573
002530 oleic acid 000112801
002531 hydroxyethylcellulose 009004620
002532 hypromellose 009004653
002902 Triacetin 000102761
005872 silicon dioxide 063231674
008846 Ammonia Water 001336216
010097 Polydextrose 068424044
010161 Dibutyl Sebacate 000109433
BLACK BOX WARNING: IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs. DIVALPROEX SODIUM EXTENDED-RELEASE - ORAL (dye-VAL-pro-ex) COMMON BRAND NAME(S): Depakote ER WARNING: Rarely, this medication has caused serious (sometimes fatal) liver problems, usually within the first 6 months of starting treatment. Laboratory tests should be performed before you start treatment and periodically during treatment, especially within the first 6 months, to monitor this side effect. The risk of serious liver problems is increased in children younger than 2 years, especially if they have an inherited metabolic disorder, severe seizure disorder with mental retardation, organic brain disease, or if they take more than one seizure medication. Talk with the doctor about the risks and benefits of using this medication in children younger than 2 years. Due to an increased risk for liver problems, people with certain inherited metabolic disorders (such as Alpers-Huttenloch
